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Abstract
Background: Multipotent mesenchymal stromal cells (MSC) enhance viability and function of islets of Langerhans.
We aimed to examine the interactions between human MSC and human islets of Langerhans that influence the
function of islets.
Methods: Human MSC and human islets (or pseudoislets, obtained after digestion and reaggregation of islet cells)
were cocultured with or without cellular contact and glucose-stimulated insulin secretion assays were performed to
assess cell function. The expression of several adhesion molecules, notably ICAM-1 and N-cadherin on islets and
MSC, was investigated by qPCR. The role of N-cadherin was analyzed by adding an anti-N-cadherin antibody in
islets cultured with or without MSC for 24 h followed by insulin measurements in static incubation assays. Islets and
MSC were coencapsulated in new hydrogel microspheres composed of calcium alginate and covalently crosslinked
polyethylene glycol. Encapsulated cells were transplanted intraperitoneally in streptozotocin-induced diabetic mice
and glycemia was monitored. Islet function was evaluated by the intraperitoneal glucose tolerance test.
Results: In vitro, free islets and pseudoislets cocultured in contact with MSC showed a significantly increased
insulin secretion when compared to islets or pseudoislets cultured alone or cocultured without cell-to-cell contact
with MSC (p < 0.05). The expression of ICAM-1 and N-cadherin was present on islets and MSC. Blocking N-cadherin
prevented the enhanced insulin secretion by islets cultured in contact with MSC whereas it did not affect insulin
secretion by islets cultured alone. Upon transplantation in diabetic mice, islets microencapsulated together with
MSC showed significantly prolonged normoglycemia when compared with islets alone (median 69 and 39 days,
respectively, p < 0.01). The intraperitoneal glucose tolerance test revealed an improved glycemic response in mice
treated with islets microencapsulated together with MSC compared to mice transplanted with islets alone (p < 0.001).
Conclusions: MSC improve survival and function of islets of Langerhans by cell-to-cell contact mediated by the
adhesion molecule N-cadherin.
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Background
Multipotent mesenchymal stromal cells (MSC) present
immunomodulatory properties [1–3], thereby reducing
the cell-mediated immune response [4]. MSC secrete
bioactive molecules that improve tissue regeneration by
increasing vascularization [5–9], angiogenesis [10] and
reducing apoptosis [5]. Cotransplantation of islets and
MSC results in improved islet graft survival and function
as demonstrated by syngeneic and allogeneic trans-
plantation models in rodents and non-human primates
[4–6, 9, 11], in a rat-to-mouse xenotransplantation
model [3, 7], and in a human to diabetic humanized
NOD scid gamma mouse model [12]. However, the
functionality of human islets cotransplanted with hu-
man MSC into immunocompetent diabetic mice has, to
our knowledge, not so far been investigated. In a setting
of human to mouse transplantation, immune rejection
is massive and needs to be overcome by immunosup-
pressive treatments. As a strategy to avoid such treat-
ments, semipermeable microcapsules can be used to
protect cells from the host immune reaction [13, 14].
Semipermeable microcapsules allow the exchanges of
nutrients, oxygen, and small molecules (lower than
100 kDa) necessary for maintaining viability of cells [15].
Hence, for the human to mouse islet transplantation we
used newly developed biomaterials enabling ionotropic
interaction between alginate (Alg) molecules and covalent
crosslinking between poly(ethylene glycol) (PEG) deriva-
tives, which have higher mechanical resistance compared
to Alg [16].
Further, the molecular mechanism leading to improved
islet graft survival and function is unclear. Several studies
attributed the beneficial effect to factors released by MSC
[17] and also to regulatory effects on the host immune
system [4]. It is not known whether direct cell contact be-
tween islets and MSC plays a role in the beneficial effects
of MSC on islet function. However, adhesion molecules
such as cadherins and integrins are expressed in human
islets [18, 19] and play a role in regulating insulin secre-
tion. Notably, cadherin interactions on beta cells play a
role in increased insulin secretion after glucose stimula-
tion [20] and are implicated in protecting islets from
apoptosis [21]. Morphological analysis of human islets
demonstrated dispersed alpha and beta cells [22], and only
recently structures of subislets have been identified, where
alpha cells are organized around centrally located beta
cells [23]. This cell arrangement, based on cell interactions
between alpha cells and beta cells, and also with stromal
cells around islets, is important for an optimal insulin re-
sponse by beta cells [24]. Further, this particular arrange-
ment is not present in so-called pseudoislets, which are
islet cell aggregations obtained in vitro after enzymatic
islet dissociation, but reappears after transplantation in
mice [25]. The mechanism leading to this rearrangement
remains unclear, but likely involves exogenous factors de-
rived from the host environment.
Hence, in this study we analyzed the effect of MSC on
islet function as well as their effect on morphology and
function of pseudoislets, implying an increased cell
contact between MSC and alpha and beta cells. We ob-
served an increased insulin secretion from islets in con-
tact with human MSC in vitro, which prompted us to
investigate a possible involvement of intercellular adhe-
sion molecules, such as epithelial (E)-cadherin, neural
cell adhesion molecule (NCAM), epithelial (Ep)CAM-1,
vascular (V)CAM-1, N-cadherin, and intercellular (I)CAM-
1. Furthermore, we aimed to assess the function of human
islets coencapsulated with MSC upon transplantation in
diabetic mice.
Methods
Isolation and culture of human pancreatic islets and
human MSC
Human islets were isolated following the Ricordi proto-
col [26], and their purity was assessed after dithizone
staining and calculated using Metamorph (Universal
Imaging, West Chester, PA, USA). Islets used for these
experiments were 80–100% pure, and no handpicking
was performed. Human islets were provided for research
only when considered not suitable for clinical transplant-
ation, through the JDRF award 1-RSC-2014-100-1-X,
ECIT Islet for Basic Research program. The amount of
islets was expressed in islet equivalents (IEQ), normal-
izing each islet to an average diameter of 150 μm. We
considered that 1 IEQ contains 103 cells. Islets were
cultured in HEPES-buffered CMRL1066 medium supple-
mented with 5.6 mmol/L glucose (Gibco-Invitrogen,
Basel, Switzerland), 100 IU/ml penicillin, 100 mg/ml
streptomycin (P-S; Gibco-Invitrogen), and 10% FCS
(Gibco-Invitrogen) (complete CMRL) at 37 °C in hu-
midified air containing 5% CO2.
MSC were obtained from the femoral head of patients
undergoing total hip replacement as described previ-
ously and characterized by FACS analysis and their abil-
ity to differentiate into osteoblasts, chondrocytes, and
adipocytes [27]. Informed consent was given by all pa-
tients and the experimental procedure was approved by
the local ethical committee of the University Hospitals
of Geneva (NAC 01-015). Briefly, MSC were purified from
crushed bone marrow by gradient centrifugation, and then
cultured in Iscove’s modified Dulbecco’s medium
(Cambrex, Verviers, Belgium) supplemented with 10%
FCS, P-S, and 10 ng/ml platelet-derived growth factor
BB (PDGF-BB; PeproTech EC Ltd, London, UK) [28].
MSC from three different donors between passages 2
and 4 were used and were cultured at 37 °C in humidi-
fied air containing 5% CO2.
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Preparation and culture of pseudoislets
Single islet cell suspensions and pseudoislets were pre-
pared as described previously [23, 25]. Briefly, islets were
rinsed in PBS (Gibco-Invitrogen) without calcium and
incubated for 7 min in Accutase cell detachment solu-
tion (Sigma, St Louis, MO, USA) with occasional mixing
by pipetting. The resultant single cell suspension was di-
luted with CMRL supplemented with 10% FCS to stop
the enzyme activity. Dissociated islet cells were counted
and were cultured overnight at a density of 5 × 105 cells
in nonadherent 10-cm diameter Petri dishes in complete
CMRL. To obtain pseudoislets, single islet cells (104 cells),
with or without MSC at a ratio of 3:1, were taken in 40 μl
of complete CMRL or MSC-conditioned medium and
placed as microdroplets in the Petri cover, which was
inverted to allow cell reaggregation and formation of
pseudoislets in the hanging microdroplets. After 3 days,
microdroplet medium was renewed and after 6 days
microdroplets were collected. Cell clusters recovered from
10 microdroplets (105 islet cells) per well, alone or with
MSC, were used for the insulin secretion assay. To obtain
MSC-conditioned medium, MSC were cultured in 75 cm2
flasks at 80% confluence in complete CMRL and medium
was recovered after 48 h. Experiments were performed in
triplicate in a 24-well plate. Histology was performed after
a 6-day culture.
Insulin secretion assays
Insulin secretion assay was performed as described pre-
viously [29]. Briefly, cells were incubated subsequently
for 1 h at 37 °C in basal condition (2.8 mmol/L glucose),
stimulated condition (16.7 mmol/L glucose), and stimu-
lated condition containing additionally 5 mmol/L theo-
phylline, to induce maximal insulin secretion. At the end
of the assay, the total amount of insulin was extracted
with acidic ethanol solution (0.18 mol/L HCl in 70%
ethanol). Islets alone (150 IEQ), islets cocultured with
MSC (15,000 cells) in cell–cell contact, and islets cocul-
tured with MSC in permeable transwell plates were
seeded (cell ratio 10:1) in triplicate in 24-well plates for
3 days in complete CMRL. For blocking experiments,
antibodies (25 μg/ml) were added 24 h before perform-
ing the secretion assay: either low-endotoxin-azide-free
(LEAF) purified anti-human CD325 (N-cadherin), ultra-
LEAF purified mouse IgG1κ isotype control (Biolegend,
San Diego, CA, USA), or anti-human ICAM-1 antibody
(CD54) (R&D Systems, Abingdon, UK). Secreted insulin
was measured by ELISA (Mercodia, Uppsala, Sweden),
following the manufacturer’s instructions. Values were
normalized to the total amount of insulin measured,
which was obtained after total cell lysis with acid ethanol.
The values of insulin secretion were expressed as the fold
increase where the basal condition was set as 1. All ex-
periments were performed in triplicate.
Real-time RT-PCR
Gene expression of adhesion molecules was analyzed by
real-time reverse transcription PCR (RT-PCR), as de-
scribed previously [27]. To analyze the expression of ad-
hesion molecules in islets and MSC, both were cultured
individually for 72 h and total RNA was extracted using
the Qiagen RNeasy Mini kit (Qiagen, San Diego, CA, USA)
according to the manufacturer’s instructions. Primers
(listed in Additional file 1: Table S1) were designed using
Primer3 online software (http://primer3.ut.ee), tested with
Primer Biosoft (http://www.premierbiosoft.com), and
blasted on BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Cell microencapsulation
The polymer for cell microencapsulation consisted of 5%
PEG-8-40 mixed in 1.5% sodium (Na)-Alg, prepared as
described previously [30]. Islets alone or with MSC were
centrifuged at room temperature (320 × g for 2 min) and
the pellet was gently mixed with Na-Alg/PEG-8-40 solu-
tion (ratio 10–12 islet cells:1 MSC). Microspheres were
generated under sterile conditions using the Encapsulator
B-395 Pro (Büchi Labortechnik AG, Flawil, Switzerland):
the solution in the gelation bath comprised 10 mM
MOPS, 100 mM CaCl2, and three equivalents of dithio-
threitol. Microsphere formation by ionotropic interaction
occurred immediately after extrusion in the gelation bath
and was completed by covalent crosslinking during subse-
quent stirring for 30 min in the gelation bath. Alg-PEG
microspheres were collected by filtration and washed
twice in physiological saline (NaCl, 0.9%) for 10 min to
eliminate remaining dithiothreitol.
Islet transplantation
Animal research was performed following protocols ap-
proved by the Geneva cantonal veterinary authorities
(license GE/34/13). Diabetes was induced in C57BL/6
male mice (Janvier, France) by intraperitoneal injection of
streptozotocin (Sigma, Buchs, Switzerland) at 220 mg/kg.
Diabetes was defined as a blood glucose level > 20 mmol/
L. Three days after injection, diabetic mice were trans-
planted. Animals, anesthetized with isoflurane, were trans-
planted with 4500–5000 IEQ encapsulated islets, with or
without MSC (cell ratio 10–12:1) representing a volume
of 700 μl of microcapsules, into the peritoneum through a
small incision. The peritoneal cavity was used as the site
for implantation of capsules, since it has the capacity to
receive the high volume of capsules needed to reverse dia-
betes. Blood glucose was measured 48 h after transplant-
ation and thereafter twice weekly. Islet graft failure was
concluded when the glucose level was > 20 mmol/L for
three consecutive measurements.
Pseudoislets (with or without MSC) obtained after the
in vitro formation were transplanted under the kidney
capsule. Because the purpose of this experiment was to
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analyze the morphology of pseudoislets alone or with
MSC in vivo, nonencapsulated pseudoislets were trans-
planted in nondiabetic immunodeficient SCID mice
under the kidney capsule, which allowed histological
analysis to be performed. Kidneys were retrieved for
histological analyses of the graft. Mouse kidneys were
collected at day 15 after transplantation.
Experimental design of insulin secretion assays and
transplantation
For insulin secretion assays using islets or islets with
blocking antibodies, comparisons were made for islets
alone, islets/MSC in contact, and islets/MSC without
contact.
For insulin secretion assays using pseudoislets, com-
parisons were made for pseudoislets alone, pseudoislets/
MSC, and pseudoislets/MSC conditioned medium.
For transplantation of microcapsules in mice, compari-
sons were made for microcapsules containing islets
alone and islets/MSC.
In each experimental setting, islets and MSC derived
from two distinct donors (allogeneic) were used.
Intraperitoneal glucose tolerance test
Fifteen days after transplantation, overnight fasted animals
were subjected to the intraperitoneal glucose tolerance
test (IPGTT). Glucose (2 g/kg) was injected intraperitone-
ally and glucose measurements were performed on blood
samples collected by tail excision at 0, 5, 15, 30, 60, and
120 min.
Histological analyses
Pseudoislets after 6 days culture were formalin fixed and
paraffin embedded using Histogel (Thermo Scientific,
Waltham, MA, USA) following the manufacturer’s rec-
ommendations. Four-micrometer sections were treated
with 0.01 mol/l citrate for 15 min in a microwave to
unmask epitopes. To avoid nonspecific binding, slides
were incubated with 0.5% BSA for 30 min at room
temperature.
For detection of MSC, sections were stained with mouse
anti-human vimentin antibody, diluted 1:50 (Dako, Glostrup,
Denmark), and with Alexa Fluor 488 goat anti-mouse
antibody (Life Technologies, CA, USA). For detection
of islet cells, sections were stained with guinea pig anti-
porcine insulin, diluted 1:500 (Dako), donkey anti-guinea
pig coumarin AMCA, diluted 1:300 (Jackson Immunore-
search, West Grove, PA, USA), rabbit anti-human gluca-
gon antibody, diluted 1:100 (Merck Millipore, Darmstadt,
Germany), and Alexa Fluor 555 donkey anti-rabbit anti-
body (Life Technologies). Microscopic images were ac-
quired using a fluorescence microscope (Mirax Midi,
Zeiss, Germany) and Pannoramic Viewer (3DHISTECH,
Hungary), and confocal laser scanning microscopy was
performed using LSM700 equipment (Zeiss).
Statistical analysis
GraphPad Prism software was used. The Mann–Whitney
nonparametric test and Wilcoxon signed-rank test were
used for in vitro tests, and the nonparametric Kaplan–
Meier survival curve and Mantel–Cox tests were used to
evaluate the statistical significance for in-vivo graft
survival data. For IPGTT the AUC was calculated and
values were compared using the parametric t test.
Differences were considered significant when p < 0.05,
p < 0.01, or p < 0.001.
Results
MSC improve insulin secretion by human islets in direct
cell–cell contact
After 3 days of culture, islets alone (islets), islets in direct
contact with MSC (islets–MSC contact), and islets and
MSC without cell–cell contact (islets–MSC no contact)
were subjected to the glucose-stimulated insulin secretion
assay. We observed a significantly higher insulin release
for islets cultured in contact with MSC than for islets cul-
tured alone (p < 0.01) and islets cultured with MSC with-
out cell–cell contact (p < 0.05) (Fig. 1a). After maximal
stimulation with theophylline, islets in contact with MSC
showed a significantly larger increase in insulin secretion
than islets alone or islets cultured with MSC without con-
tact (p < 0.01). These results show that insulin secretion
by human islets is significantly enhanced upon culture
with MSC in direct cell–cell contact.
This result prompted us to investigate whether in-
creasing the contact opportunity between MSC and islet
cells further increases insulin secretion. Therefore, we
cultured dissociated islet cells in hanging drops for 6 days
to induce formation of clusters of reaggregated cells,
called pseudoislets, without or with MSC. As control,
islet cells were cultured in hanging drops in MSC-
conditioned medium. All conditions showed similar in-
sulin secretion after high glucose stimulation. However,
upon maximal stimulation with theophylline, pseudois-
lets containing MSC revealed a significantly higher insu-
lin secretion than pseudoislets without MSC (p < 0.05)
or pseudoislets cultured in MSC-conditioned medium
(p < 0.01) (Fig. 1b): this indicates a beneficial effect of
direct cell–cell contact between MSC and islet cells
within pseudoislets. Altogether, these results show that
insulin secretion is significantly higher when MSC are in
direct cell–cell contact with islets or islet cells in
pseudoislets.
MSC serve as a stromal structure for islets
The architecture of native human islets comprises
substructures, where centrally located beta cells are
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surrounded by alpha cells. Histological analysis of
in vitro formed pseudoislets showed that alpha and
beta cells are oppositely arranged compared to native
islets. However, according to the literature the native
islet architecture reappears in pseudoislets after trans-
plantation in mice [25]. These data prompted us to as-
sess whether MSC interfere with the structural
organization of islet cells in pseudoislets during in vitro
culture, and after transplantation in mice. Pseudoislets
composed of islet cells formed islet cell clusters composed
of centrally located alpha cells, surrounded by a layer of
beta cells (Fig. 2a). Pseudoislets containing MSC showed a
similar organization of beta cells surrounding alpha cells,
and presented single MSC intermingled within alpha and
beta cells. Areas, built exclusively of MSC, fit tightly to
areas of islet cell clusters (Fig. 2b). Images acquired by
confocal laser scanning microscopy revealed a predomin-
ant localization of beta cells beside MSC (Fig. 2e).
To analyze the effect of MSC on the architecture of
pseudoislets in vivo, pseudoislets comprised of islet cells
alone or with MSC were transplanted under the kidney
capsule of nondiabetic SCID mice and analyzed 15 days
later. As shown, pseudoislets without MSC (Fig. 2c) and
with MSC (Fig. 2d) reorganized in centrally located beta
cells surrounded by alpha cells. MSC in the pseudoislet
grafts mostly localized between the substructures of the
pseudoislets. In addition, MSC localize around the pseu-
doislet graft (Fig. 2d, arrows). These results demon-
strated that MSC interact with islet cells in vitro and in
vivo, further suggesting that MSC serve as a supportive
stromal structure for islets.
Inhibition of N-cadherin decreases the enhanced insulin
secretion
To investigate whether adhesion molecules are involved
in the enhanced insulin secretion, we analyzed separ-
ately in islets and MSC the expression of E-cadherin,
NCAM, EpCAM-1, VCAM-1, N-cadherin, and ICAM-
1. E-cadherin, NCAM, and EpCAM were expressed in
islets but not in MSC (Fig. 3a–c). In contrast, VCAM-
1 was expressed only in MSC (Fig. 3d). Interestingly,
mRNA for N-cadherin and ICAM-1 were expressed both
in islets and in MSC (Fig. 3e, f ). We therefore selected
these adhesion molecules for blocking experiments in the
glucose-stimulated insulin assay.
Islets with or without MSC were cultured for 24 h in
the presence of blocking antibodies against N-cadherin
or ICAM-1 and then stimulated to release insulin. Similar
to data presented in Fig. 1, islets in contact with MSC
showed an increased insulin secretion after high glucose
(p < 0.05) and theophylline stimulation (p < 0.01) when
compared to islets alone or islets and MSC cultured separ-
ately. Upon culture in the presence of the blocking anti-
body against N-cadherin, this increase was significantly
inhibited, both for glucose stimulation (p < 0.05) and for
glucose plus theophylline stimulation (p = 0.05, Fig. 4a).
This inhibition was only observed for cultures in the
presence of MSC in direct cell–cell contact with islets.
The insulin secretion by islets cultured without MSC or
without direct contact with MSC was not affected. The
specificity of the observed effect was demonstrated in
culture using an isotype control antibody: in this condi-
tion, the enhanced insulin release upon glucose and
Fig. 1 Effect of MSC on insulin secretion by islets. The insulin secretion assay was performed by incubating islets (150 IEQ) or pseudoislets (105 islet cells)
at basal glucose (2.8 mM, white bars), high glucose concentration (16.7 mM, striped bars), and high glucose plus theophylline (16.7 and 5 mM,
respectively, black bars) for 1 h. a Islets alone (islets), together with 15 × 103 MSC (ratio 1 IEQ:100 MSC) in direct cell–cell contact (islets-MSC contact), and
islets–MSC without cell–cell contact separated in a transwell chamber (islets-MSC no contact) after 3-day culture. b Pseudoislets (p-islets), pseudoislets cul-
tured in direct cell–cell contact with 3 × 104 MSC (ratio 3:1) (p-islets MSC contact), and pseudoislets cultured in MSC-conditioned medium (p-islets MSC
cond.medium) after 6-day culture. Values are normalized to the total amount of insulin, and insulin secretion expressed as fold increase where the basal
level is set at 1. Data presented as arithmetic mean ± SEM of four or five independent islet donors respectively, and for each donor the assays were per-
formed in triplicate. Mann–Whitney test: *p < 0.05, **p < 0.01
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theophylline stimulation was not affected (Fig. 4a). Spe-
cific binding of the anti N-cadherin antibody was
assessed by FACS and N-cadherin protein expression in
islets and MSC was demonstrated by western blot ana-
lysis (see Additional file 1: Figure S1). Blocking of
ICAM-1 did not inhibit the increased insulin secretion
under stimulating conditions, irrespective of the pres-
ence of MSC in the culture (Fig. 4b). These results
demonstrate that intercellular interactions involving N-
cadherin are relevant in enhancing insulin secretion
during direct cell–cell contact between islets and MSC.
Islets microencapsulated with MSC maintain regulated
insulin secretion
To evaluate the effect of MSC on the survival and func-
tion of microencapsulated islets after transplantation,
islets with or without MSC were microencapsulated
(Fig. 5a, b). In the microspheres MSC were present in a
scattered distribution (Fig. 5b). Three days after micro-
encapsulation, insulin secretion was similar for micro-
encapsulated islets alone and microencapsulated islets
with MSC (Fig. 5c). These results show that islets main-
tained insulin secretion upon glucose stimulation, after
microencapsulation. However, early after microencap-
sulation the enhanced effect on insulin secretion by
MSC was not observed. To analyze whether the distri-
bution of MSC inside the microcapsule changed with
time, microencapsulated islets and MSC were retrieved
15 days after transplantation. Interestingly, inside the
microcapsules MSC localized with islets (see Additional
file 1: Figure S2), contrary to MSC in microcapsules before
transplantation, where MSC were present in a scattered
distribution. This indicates that after transplantation
MSC localize to islets in microcapsules and suggests
that this interaction fosters glucose-induced insulin
secretion.
Fig. 2 Alpha and beta cell arrangement in cultured pseudoislets and after transplantation in SCID mice. Islets were dissociated by enzymatic
digestion, and 104 single cells were cultured in hanging drops for 6 days prior to in vitro immunofluorescence studies, and for 8 days prior to
transplantation under the kidney capsule of SCID mice. Beta cells were immunostained for insulin (blue), alpha cells for glucagon (red), and MSC
for vimentin (green). Representative images of three different experiments. a, b Pseudoislets after in vitro formation: (a) islet cells alone, (b) islet
cells and MSC. c, d Pseudoislets 15 days after transplantation: (c) pseudoislets composed of islet cells alone, (d) pseudoislets composed of islet
cells and MSC. White arrows indicate vimentin-positive cells within the islet graft located outside of the alpha and beta cell arrangements (islet
substructures). e Right panel: in vitro formed islets and MSC at day 6, confocal laser scanning microscopy
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MSC prolong survival and function of microencapsulated
human islets in diabetic mice
Free islets, microencapsulated islets, and microencapsu-
lated islets with MSC were transplanted into the peri-
toneum of immunocompetent diabetic C57BL/6 mice. In
the immediate post-transplant period, all mice reversed
diabetes (Fig. 6a). Mice transplanted with free islets
then rapidly lost normoglycemia and became diabetic:
the median normoglycemia time was 6 days. Mice
transplanted with microencapsulated islets remained
normoglycemic until day 18 and then progressively
turned diabetic starting at day 20: the median survival
time was 39 days. This difference in survival between
free and microencapsulated islets was statistically sig-
nificant (p < 0.0001). The period of normoglycemia was
significantly longer in mice that received microencapsu-
lated islets with MSC, resulting in a survival period up
to 88 days and a median survival of 69 days (p < 0.01
compared to microencapsulated islets, Fig. 6b). After
graft failure, no insulin-positive cells were found in re-
covered beads originally containing islets alone (Fig. 6c).
However, insulin-positive cells were still present in
beads where islets were coencapsulated with MSC
(Fig. 6d). These results demonstrate that MSC pro-
longed human islet graft survival in vivo.
To assess graft function in vivo, the IPGTT was per-
formed at day 15 after transplantation in untreated
healthy control mice and diabetic mice transplanted with
microencapsulated islets. Blood glucose levels increased
2.6 and 2.4 times over basal glucose levels at time 0,
respectively, and recovered to normoglycemia 2 h after
injection (ratio 1.2 and 1.3 compared to the basal con-
centration). Diabetic mice transplanted with microen-
capsulated islets with MSC manifested lower blood
glucose levels than healthy mice at time 0 (4.1 mmol/L
compared to 9.1 mmol/L): however, these mice did
not show any manifestation of hypoglycemia (weight
loss, decreased movements, and erected haircoat).
Moreover, after glucose stimulation, these mice
showed a lower increase in blood glucose levels (2.0
times compared to time 0) and also presented lower
levels after 2 h compared to time 0 (1.2 mmol/L, ratio
0.3). This lower glucose response in comparison with
mice transplanted with microencapsulated islets alone
Fig. 3 Gene expression of adhesion molecules in islets and MSC. Quantitative RT-PCR was performed to assess adhesion molecule expression and
values were normalized to the expression of housekeeping ribosomal protein large P0. Expression of epithelial (E)-cadherin (a), neural cell
adhesion molecule (NCAM) (b), epithelial (Ep)CAM-1 (c), vascular (V)CAM-1 (d), N-cadherin (e), and intercellular (I)CAM-1 (f) measured in islets
(white boxes) and MSC (black boxes) after a 3-day culture period. Data from three islet donors presented as floating bars (minimum to maximum)
with the line presenting the mean value
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reached statistical significance (p < 0.001, Fig. 6e).
Altogether, these results indicate that human islets
coencapsulated with human MSC display a more effi-
cient glucose-induced insulin response in vivo com-
pared to islets alone.
Discussion
Transplantation of microencapsulated islets without
chronic immunosuppression represents a valuable thera-
peutic option for type 1 diabetic patients, potentially resolv-
ing current hurdles associated with clinical transplantation
Fig. 4 Blocking of N-cadherin but not of ICAM-1 decreased the MSC-enhanced insulin secretion. Antibodies against N-cadherin, ICAM-1, and isotype
control were added to the culture of islets (islets), islets and MSC in coculture with cell–cell contact (islets MSC contact) and islets and MSC in culture
without contact (islets MSC no contact) for 24 h prior to the insulin secretion assay. Cells were incubated in basal glucose (2.8 mM, white bars), high
glucose concentration (16.7 mM, striped bars), and high glucose plus theophylline (16.7 and 5 mM, respectively, black bars) for 1 h. Data are presented
as in Fig. 1. a Cells cultured alone and with the addition of 25 μg/ml anti-N-cadherin antibody and isotype control. b Cells cultured alone and with the
addition of 25 μg/ml anti-ICAM-1 antibody. Values of secreted insulin are normalized to the total amount of insulin and expressed as fold increase
where the basal level was set at 1. Human islets from four and three different donors used for N-cadherin and ICAM-1 blocking experiments,
respectively. For each donor the experiment was performed in triplicate. Each graph represents mean ± SEM. Mann–Whitney test: *p < 0.05,
**p < 0.01, ***p < 0.001
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of free islets, such as the adverse side effects of im-
munosuppressive drugs. However, as for free islets,
transplantation of microencapsulated islets does not
provide permanent independence from exogenous insu-
lin, and the microencapsulation technology needs fur-
ther improvements to achieve long-term graft function.
Studies in diabetic mice and rats have shown that MSC
upon cotransplantation with islets are beneficial for
islet function and survival [31]. There are only a few
studies in the literature addressing the effect of human
MSC on human islets [32–34], which prompted us to
assess whether bone marrow-derived human MSC sus-
tain human islet function in vitro and in vivo.
Human islets upon culture with MSC show enhanced
insulin secretion in response to glucose and theophylline
stimulation (Fig. 1). This potentiating effect of MSC was
observed solely when islets and MSC were cocultured in
direct cell–cell contact. This observation is supported by
findings in rodents, where the contact between MSC
and rat islets maintained and increased glucose-induced
insulin secretion [35, 36]. Rat islets manifested improved
viability when cocultured with MSC at days 7 and 14
[37]; however, in our experimental in vitro conditions,
where we performed insulin secretion assays after 3 days
of coculture, islet viability was not influenced since total
insulin amounts, obtained by extraction with acid ethanol,
were comparable in all conditions. Based on the potentiat-
ing effect of MSC on insulin secretion, we assessed the
direct cell–cell contact between human islet cells and
MSC in pseudoislet formation. It has been described that
alpha and beta cells in islets reorganize after transplant-
ation of pseudoislets in SCID mice [25]. In the present
study, MSC did not alter the arrangement of alpha and
beta cells but located between the reorganized sub-
structures, suggesting the integration of MSC as a stro-
mal tissue component in the pseudoislets (Fig. 2).
In mice, optimal regulation of insulin secretion by
beta cells is dependent on N-cadherin as demonstrated
for a pancreatic epithelium-specific knockout of N-
cadherin: N-cadherin controls insulin granule turnover
Fig. 5 Microencapsulated islets maintain regulated insulin secretion. a, b Phase contrast images of Alg-PEG microencapsulated islets (104 IEQ/ml
Alg-PEG) (a) and islets coencapsulated with 8 × 105 MSC (b). c Insulin secretion by microencapsulated islets (islets Alg-PEG) and islets coencapsulated
with MSC (islets-MSC Alg-PEG) at 3 days after encapsulation. Microencapsulated islets (150 IEQ) were incubated at basal glucose (2.8 mM, white bars),
high glucose concentration (16.7 mM, striped bars), and high glucose plus theophylline (16.7 and 5 mM, respectively, black bars) for 1 h. Values
of secreted insulin are normalized to the total insulin amount and expressed as fold increase where the basal level was set at 1. Data
presented as mean value ± SEM of three islet donors, and for each donor the assay was performed in triplicate. Wilcoxon signed-rank
test: ***p < 0.001
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and subsequent insulin secretion [38]. Further, N-
cadherin promoted insulin secretion upon stimulation
of human beta cells [20]. N-cadherin is expressed in
human islets and strongly in human MSC, which led us
to investigate the potential role of N-cadherin in the
enhanced insulin secretion in coculture with MSC.
Blocking N-cadherin interactions for 24 h did not affect
insulin expression, since the total amount of insulin
was similar in all conditions (data not shown) but abol-
ished the enhanced insulin secretion by islets cocultured
with MSC in direct cell–cell contact (Fig. 4a). We con-
cluded that enhanced islet function induced in direct
cell–cell contact with MSC requires N-cadherin interactions.
Further, we investigated the effect of human MSC on
graft function of microencapsulated human islets in dia-
betic immunocompetent mice. For transplantation stud-
ies, we focused on nondissociated islets since insulin
secretion by pseudoislets containing MSC was equiva-
lent compared to nondissociated islets in contact with
MSC. This demonstrated that increased contact between
islet cells and MSC compared to nondissociated islets
did not further increase insulin secretion. The microen-
capsulation itself prevented acute graft failure due to re-
jection, from a median survival of 6 days for free islets
to a median normoglycemia period of 39 days for micro-
encapsulated islets (Fig. 6b). Coencapsulation of islets
and MSC resulted in a further significant prolongation
of survival up to 69 days. The IPGTT showed lower
blood glucose levels in mice transplanted with islets
coencapsulated with MSC (Fig. 6e), which might be at-
tributed to an increased insulin production by islets in
the presence of MSC. This phenomenon could also be
related to the fact that the presence of MSC in micro-
capsules protects islets against proinflammatory cytokines.
This had been shown in coculture studies, in which hu-
man MSC but not human dermal fibroblasts preserved
human islets exposed to proinflammatory cytokines [34].
Interestingly, in a pig-to-nonhuman primate xenotrans-
plantation model, the presence of pig MSC in capsules
containing pig islets improved oxygenation and neoangio-
genesis but only a minor improvement in long-term islet
function was observed [39]. Others have shown that the
Fig. 6 Islet survival and function in diabetic mice. Islets (4.5 × 103–5 × 103 IEQ) were transplanted into streptozotocin-induced diabetic mice. Mice
were transplanted with free islets (n = 6), with microencapsulated islets (n = 12), or with islets coencapsulated with MSC (n = 10) at IEQ:MSC ratio
1:80. a Glycemia measurements 48 h after transplantation and thereafter twice weekly. Islet graft failure concluded when glucose level was >
20 mmol/L for three consecutive measurements. Dotted line, glucose measurements in 12 mice transplanted with encapsulated islets; dashed
line, glucose measurements in 10 mice transplanted with encapsulated islets and MSC. b Kaplan-meier curve representing the % of graft survival.
Continuous line, mice transplanted with free islets; dotted line, mice transplanted with microencapsulated islets; dashed line, mice trasplanted with
islets coencapsulated with MSC. Mantel–Cox test performed. c, d Beads were retrieved from the peritoneum when mice became diabetic. Sections were
immunostained against insulin (red) and vimentin (green) for islets and MSC, respectively. Cell nuclei were stained with Hoechst (blue). c Beads recovered
from mice transplanted with islets alone. Only empty beads were retrieved. d Beads recovered from mice transplanted with islets and MSC together still
contained some islets. e Intraperitoneal glucose tolerance test performed at day 15 in nontransplanted healthy mice (n= 3, continuous line), in diabetic mice
transplanted with alginate-PEG islets (n= 3, dotted line), and in mice transplanted with alginate-PEG islets +MSC (n= 10, dashed line). A single intraperitoneal
injection of glucose (2 g/kg) performed at time 0 and glucose monitored at 0, 5, 10, 15, 30, 45, 60, and 120 min thereafter. Values expressed as the mean ±
SEM of measurement from at least three mice. Area under the curve is calculated to perform t-test statistical analysis
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presence of kidney-derived MSC in microencapsulated
mouse islets improved graft outcome, even in the absence
of MSC-mediated enhancement of revascularization and
preservation of islet morphology [31]. Recently, MSC have
been described to serve as a “multifunctional islet sup-
portive carrier” for the housing of pancreatic islets in a
three-dimensional coculture [40]. Therefore, in order to
establish standardized protocols for future application
of MSC in clinics, precise mechanisms leading to the
supportive effect on islets need to be unraveled.
The strength of this work is based on the finding that
molecular interactions of N-cadherin between human islets
and MSC are essential for the increased insulin response
by islets cocultured with MSC. However, the transplant-
ation setting using encapsulated islets and MSC has
some limitations. It remains to be investigated whether
N-cadherin interactions are involved in the enhanced
and prolonged graft function observed in the coencap-
sulation setting or whether trophic factors released by
MSC are also implicated.
Conclusions
The present study is the first to show that MSC improved
survival and function of microencapsulated human islets
transplanted in mice. Altogether, our data suggest that
MSC via N-cadherin interactions provide an optimal
microenvironment for fine-tuning of insulin secretion
and that MSC interactions could be pivotal to support
islet graft function in clinical islet transplantation.
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